Correction
This article was originally published in The Tan Sheet
Executive Summary
In the article "Prevacid Initial Launch Efforts To Focus On Switching Prescription Users," (1"The Tan Sheet" May 18, 2009, p. 3), we inadvertently implied that Novartis intends to market Prevacid 24HR to current users of prescription Prevacid for gastroesophageal reflux disease. We should have said the firm aims to market Prevacid 24HR to the subset of its Rx patients that suffer from frequent heartburn. "The Tan Sheet" regrets the misstatement
You may also be interested in...
Prevacid Initial Launch Efforts To Focus On Switching Prescription Users
Novartis plans to prioritize converting patients currently treated with prescription Prevacid when the proton pump inhibitor becomes available over-the-counter, rather than winning over Prilosec OTC users, a Novartis executive said
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.